已收盤 02-06 16:00:00 美东时间
-0.001
-12.50%
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type
2024-09-27 15:03
-- Cash Balance of $52.9 million to fund operations well into 2024 ---- Initiat...
2022-03-31 04:34
Newest member is a renowned thought leader in the identification of neurobiolog...
2022-02-09 21:06
MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp...
2021-11-24 22:00